SMTP-7, a new thrombolytic agent, decreases hemorrhagic transformation after transient middle cerebral artery occlusion under warfarin anticoagulation in mice

Brain Research

Volumn 1578, Issue , 2014, Pages 38-48

  Ito, Akira ^a   Niizuma, Kuniyasu ^a   Shimizu, Hiroaki ^b   Fujimura, Miki ^a   Hasumi, Keiji ^c,d   Tominaga, Teiji ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^d Division of Research and Development   (Japan)

Author keywords

Cerebral infarction; Focal ischemia; Hemorrhagic transformation; Recombinant tissue plasminogen activator; Thrombolysis; Warfarin

Indexed keywords

DRINKING WATER; FIBRINOLYTIC AGENT; SMTP 7; UNCLASSIFIED DRUG; WARFARIN; 2 PYRROLIDONE DERIVATIVE; ANTICOAGULANT AGENT; BENZOPYRAN DERIVATIVE; GELATINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BASEMENT MEMBRANE; BLEEDING; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN INFARCTION; CONTROLLED STUDY; FEEDING; HEMORRHAGIC TRANSFORMATION; HYPOTHESIS; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; SUTURE; ANIMAL; C57BL MOUSE; CEREBRAL HEMORRHAGE; COMPLICATION; DRUG EFFECTS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; METABOLISM;

ANIMALIA; MUS; STACHYBOTRYS MICROSPORA;

ANIMALS; ANTICOAGULANTS; BENZOPYRANS; BLOOD-BRAIN BARRIER; CEREBRAL HEMORRHAGE; FIBRINOLYTIC AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; PYRROLIDINONES; WARFARIN;

EID: 84926137671     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2014.07.004     Document Type: Article

References (40)

1. Adams Jr., H.P., del Zoppo, G., Alberts, M.J., Bhatt, D.L., Brass, L., Furlan, A., Grubb, R.L., Higashida, R.T., Jauch, E.C., Kidwell, C., Lyden, P.D., Morgenstern, L.B., Qureshi, A.I., Rosenwasser, R. H., Scott, P.A., Wijdicks, E.F., 2007. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 115, e478-e534.
2. Akamatsu, Y., Saito, A., Fujimura, M., Shimizu, H., Mekawy, M., Hasumi, K., Tominaga, T., 2011. Stachybotrys microspora triprenyl phenol-7, a novel fibrinolytic agent, suppresses superoxide production, matrix metalloproteinase-9 expression, and thereby attenuates ischemia/reperfusion injury in rat brain. Neurosci. Lett. 503, 110-114.
3. Akamatsu, Y., Shimizu, H., Saito, A., Fujimura, M., Tominaga, T., 2012. Consistent focal cerebral ischemia without posterior cerebral artery occlusion and its real-time monitoring in an intraluminal suture model in mice. J. Neurosurg. 116, 657-664.
4. Albers, G.W., Bates, V.E., Clark, W.M., Bell, R., Verro, P., Hamilton, S.A., 2000. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the standard treatment with alteplase to reverse stroke (STARS) study. J. Am. Med. Assoc. 283, 1145-1150.
5. Aronowski, J., Strong, R., Shirzadi, A., Grotta, J.C., 2003. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke 34, 1246-1251.
6. Berger, C., Fiorelli, M., Steiner, T., Schabitz, W.R., Bozzao, L., Bluhmki, E., Hacke, W., von Kummer, R., 2001. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic?. Stroke 32, 1330-1335.
7. Charo, I.F., Ransohoff, R.M., 2006. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610-621.
8. Chen, C.H., Toung, T.J., Sapirstein, A., Bhardwaj, A., 2006. Effect of duration of osmotherapy on blood-brain barrier disruption and regional cerebral edema after experimental stroke. J. Cereb. Blood Flow Metab. 26, 951-958.
9. Clark, W.M., Lessov, N.S., Dixon, M.P., Eckenstein, F., 1997. Monofilament intraluminal middle cerebral artery occlusion in the mouse. Neurol. Res. 19, 641-648.
10. Del Zoppo, G.J., Saver, J.L., Jauch, E.C., Adams Jr., H.P., 2009. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 40, 2945-2948.
11. Foerch, C., Arai, K., Jin, G., Park, K.P., Pallast, S., van Leyen, K., Lo, E.H., 2008. Experimental model of warfarin-associated intracerebral hemorrhage. Stroke 39, 3397-3404.
12. Forrester, K.R., Stewart, C., Tulip, J., Leonard, C., Bray, R.C., 2002. Comparison of laser speckle and laser Doppler perfusion imaging: measurement in human skin and rabbit articular tissue. Med. Biol. Eng. Comput. 40, 687-697.
13. Fujimura, M., Morita-Fujimura, G.Y., Massengale, Y., Kawase, J., Chan, PH, M., 1999. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res. 842, 92-100.
14. Garcia-Yebenes, I., Sobrado, M., Zarruk, J.G., Castellanos, M., Perez de la Ossa, N., Davalos, A., Serena, J., Lizasoain, I., Moro, M.A., 2011. A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke. Stroke 42, 196-203.
15. Gasche, Y., Copin, J.C., Sugawara, T., Fujimura, M., Chan, P.H., 2001. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 21, 1393-1400.
16. Group T.N.I.o.N.D.a.S.r.-P.S.S., 1995. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333, 1581-1587.
17. Hacke, W., Kaste, M., Fieschi, C., Toni, D., Lesaffre, E., von Kummer, R., Boysen, G., Bluhmki, E., Hoxter, G., Mahagne, M. H., et al., 1995. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). J. Am. Med. Assoc. 274, 1017-1025.
18. Hacke, W., Kaste, M., Fieschi, C., von Kummer, R., Davalos, A., Meier, D., Larrue, V., Bluhmki, E., Davis, S., Donnan, G., Schneider, D., Diez-Tejedor, E., Trouillas, P., 1998. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352, 1245-1251.
19. Hacke, W., Brott, T., Caplan, L., Meier, D., Fieschi, C., von Kummer, R., Donnan, G., Heiss, W.D., Wahlgren, N.G., Spranger, M., Boysen, G., Marler, J.R., 1999. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 53, S3-14.
20. Hashimoto, T., Shibata, K., Nobe, K., Hasumi, K., Honda, K., 2010. A novel embolic model of cerebral infarction and evaluation of Stachybotrys microspora triprenyl phenol-7 (SMTP-7), a novel fungal triprenyl phenol metabolite. J. Pharmacol. Sci. 114, 41-49.
21. Hasumi, K., Yamamichi, S., Harada, T., 2010. Small-molecule modulators of zymogen activation in the fibrinolytic and coagulation systems. FEBS J. 277, 3675-3687.
22. Hu, W., Hasumi, K., 2000. Activation of fibrinolysis by SMTP-7 and -8, novel staplabin analogs with a pseudosymmetric structure. J. Antibiot. (Tokyo) 53, 241-247.
23. Hu, W., Narasaki, R., Nishimura, N., Hasumi, K., 2012. SMTP (Stachybotrys microspora triprenyl phenol) enhances clot clearance in a pulmonary embolism model in rats. Thromb. J. 10, 2.
24. Kasahara, Y., Nakagomi, T., Matsuyama, T., Stern, D., Taguchi, A., 2012. Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. Stroke 43, 499-506.
25. Kilic, E., Kilic, U., Matter, C.M., Luscher, T.F., Bassetti, C.L., Hermann, D.M., 2005. Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase. Stroke 36, 332-336.
26. Lapchak, P.A., Chapman, D.F., Zivin, J.A., Hsu, C.Y., 2000. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke editorial comment. Stroke 31, 3034-3040.
27. Li, M., Zhang, Z., Sun, W., Koehler, R.C., Huang, J., 2011. 17beta-estradiol attenuates breakdown of blood-brain barrier and hemorrhagic transformation induced by tissue plasminogen activator in cerebral ischemia. Neurobiol. Dis. 44, 277-283.
28. Miyazaki, T., Kimura, Y., Ohata, H., Hashimoto, T., Shibata, K., Hasumi, K., Honda, K., 2011. Distinct effects of tissue-type plasminogen activator and SMTP-7 on cerebrovascular inflammation following thrombolytic reperfusion. Stroke 42, 1097-1104.
29. Pfefferkorn, T., Rosenberg, G.A., 2003. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34, 2025-2030.
30. Pfeilschifter, W., Spitzer, D., Czech-Zechmeister, B., Steinmetz, H., Foerch, C., 2011a. Increased risk of hemorrhagic transformation in ischemic stroke occurring during warfarin anticoagulation: an experimental study in mice. Stroke 42, 1116-1121.
31. Pfeilschifter, W., Spitzer, D., Pfeilschifter, J., Steinmetz, H., Foerch, C., 2011b. Warfarin anticoagulation exacerbates the risk of hemorrhagic transformation after rt-PA treatment in experimental stroke: therapeutic potential of PCC. PLoS One 6, e26087.
32. Pfeilschifter, W., Bohmann, F., Baumgarten, P., Mittelbronn, M., Pfeilschifter, J., Lindhoff-Last, E., Steinmetz, H., Foerch, C., 2012. Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke. Ann. Neurol. 71, 624-633.
33. Shibata, K., Hashimoto, T., Nobe, K., Hasumi, K., Honda, K., 2010. A novel finding of a low-molecular-weight compound, SMTP-7, having thrombolytic and anti-inflammatory effects in cerebral infarction of mice. Naunyn Schmiedebergs Arch. Pharmacol. 382, 245-253.
34. Shibata, K., Hashimoto, T., Nobe, K., Hasumi, K., Honda, K., 2011. Neuroprotective mechanisms of SMTP-7 in cerebral infarction model in mice. Naunyn Schmiedebergs Arch. Pharmacol. 384, 103-108.
35. Sumii, T., 2002. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33, 831-836.
36. Tagaya, M., Liu, K.F., Copeland, B., Seiffert, D., Engler, R., Garcia, J. H., del Zoppo, G.J., 1997. DNA scission after focal brain ischemia. Temporal differences in two species. Stroke 28, 1245-1254.
37. Tang, J., Li, Y.J., Mu, J., Li, Q., Yang, D.Y., Xie, P., 2009. Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats. Neurol. Res. 31, 189-194.
38. Wang, X., Lee, S.R., Arai, K., Lee, S.R., Tsuji, K., Rebeck, G.W., Lo, E. H., 2003. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat. Med. 9, 1313-1317.
39. Wang, Y.F., Tsirka, S.E., Strickland, S., Stieg, P.E., Soriano, S.G., Lipton, S.A., 1998. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med. 4, 228-231.
40. Yamashita, T., Kamiya, T., Deguchi, K., Inaba, T., Zhang, H., Shang, J., Miyazaki, K., Ohtsuka, A., Katayama, Y., Abe, K., 2009. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J. Cereb. Blood Flow Metab. 29, 715-725.v